| Literature DB >> 33625597 |
Marlene Hager1, Johannes Ott2, Christian Göbl3, Iris Holzer1, Rudolf Seemann4, Christine Kurz1, John Preston Parry5,6.
Abstract
PURPOSE: To determine whether an increase in cul de sac (CDS) fluid after hysteroscopy is predictive of tubal patency.Entities:
Keywords: Chromopertubation; Fallopian tubes; Female infertility; Hysteroscopy; Laparoscopy; Tubal patency
Mesh:
Year: 2021 PMID: 33625597 PMCID: PMC8429386 DOI: 10.1007/s00404-021-05993-0
Source DB: PubMed Journal: Arch Gynecol Obstet ISSN: 0932-0067 Impact factor: 2.344
Basic patient characteristics
| Age (years)* | 32.5 ± 5.2 |
| BMI (kg/m2)* | 24.3 ± 4.8 |
| Phase of menstrual cycle at the day of surgery# | |
| Follicular phase | 102 (88.7) |
| Luteal phase | 13 (11.3) |
| Primary sterility# | 86 (74.8) |
| Indication for surgery#+ | |
| Endometrial polyp | 4 (3.5) |
| Suspicion of endometriosis | 51 (44.3) |
| Suspicion of tubal factor | 21 (18.3) |
| Laparoscopic ovarian drilling | 11 (9.6) |
| Uterine malformation | 14 (12.2) |
| Ovarian cyst | 36 (31.3) |
| Myoma | 17 (4.8) |
| Otherwise unexplained infertility | 6 (5.2) |
Data are provided as * mean ± standard deviation or # number (frequency); + multiple mentions are possible
Comparison of sonographic pre- to post-hysteroscopic fluid shifts according to the number of patent Fallopian tubes
| Bilateral tubal patency ( | Unilateral tubal occlusion ( | Bilateral tubal occlusion ( | ||
|---|---|---|---|---|
| Visible fluid shifta | 62 (95.4) | 12 (54.5) | 1 (3.6) | < 0.001 |
| Fluid shift (mL)b | 18.0 (8.0;30.0) | 5.5 (0.0;5.3) | 0 (0;0) | < 0.001 |
aNominal variable, provided in n (%)
bContinuous variable, provided in median (IQR) ± standard deviation
Testing for bilateral Fallopian tube occlusion (A) and bilateral Fallopian tube patency (B) with pre- and post-hysteroscopy sonography to assess fluid shifts
| A | Laparoscopic chromopertubation | < 0.001 | |||
|---|---|---|---|---|---|
| Unilateral or bilateral patency | Bilateral occlusion | Sum | Sensitivity (%)# | 85.1 (75.8; 91.8) | |
| Fluid shift | |||||
| Present | 74 | 1 | Specificity (%)# | 96.4 (81.7; 99.9) | |
| Absent | 13 | 27 | PPV (%)# | 98.7 (92.8; 100.0) | |
| Sum | NPV (%)# | 67.5 (50.9; 81.4) | |||
PPV positive predictive value; NPV negative predictive value
P values were calculated either using the Fisher’s exact test
#Results are provided with the 95% confidence interval
Women without a visible fluid shift in the pouch of Douglas: comparison between patients with and without bilateral tubal occlusion
| Bilateral tubal occlusion ( | Uni- or bilateral tubal patency ( | Multivariate analysis | |||
|---|---|---|---|---|---|
| Adjusted OR (95% CI)a | |||||
| Age (years)c | 34.4 ± 4.4 | 34.6 ± 4.2 | 1.053 (0.838; 1.322) | 0.195 | 0.659 |
| Body mass index (kg/m2)c | 25.2 ± 4.5 | 24.2 ± 4.4 | 1.077 (0.787; 1.474) | 0.216 | 0.642 |
| Follicular phased | 23 (85.2) | 11 (84.6) | 0.812 (0.010; 68.664) | 0.008 | 0.927 |
| Secondary infertilityd | 7 (25.9) | 5 (38.5) | 1.806 (0.155; 21.059) | 0.222 | 0.637 |
| Any intracavitary abnormalityd,e | 2 (7.4) | 6 (46.2) | 0.038 (0.002; 0.726) | 4.724 | |
| Uterine malformationd,e | 0 | 3 (23.1) | 0 (0; –) | 0.000 | 0.999 |
| Ovarian cystd,e | 6 (22.2) | 3 (23.1) | 0.290 (0.021; 3.942) | 0.864 | 0.353 |
| Endometriosisd,e | 10 (37.0) | 5 (38.5) | 0.592 (0.055; 6.636) | 0.187 | 0.665 |
| Uni- or bilateral hydrosalpinxd,e | 3 (11.1) | 3 (23.1) | 0.130 (0.002; 7.501) | 0.972 | 0.324 |
| Adhesions covering one or both tubesd,e | 11 (40.0) | 9 (69.2) | 0.076 (0.006; 0.902) | 4.168 | |
| Myoma(s)d,e | 5 (18.5) | 2 (15.4) | 0.471 (0.028; 7.804) | 0.277 | 0.599 |
| Constant | – | – | 1.676 (–; –) | 0.009 | 0.926 |
aOR (95% CI) = odds ratio (95% confidence interval)
bLR test = likelihood ratio test
cContinuous variable, provided in mean ± standard deviation
dNominal variable, provided in n (%)
eFinal diagnosis during combined hysteroscopy/laparoscopy, multiple entries allowed
dItalic letters indicate statistical significance. “Any intracavitary abnormality” includes: endometrial polyps, intrauterine adhesions, myoma(s) FIGO 0–2, and uterine malformations